Earnings Call Summary | Beyond Air(XAIR.US) Q4 2024 Earnings Conference
Earnings Call Summary | Beyond Air(XAIR.US) Q4 2024 Earnings Conference
The following is a summary of the Beyond Air, Inc. (XAIR) Q4 2024 Earnings Call Transcript:
以下是Beyond Air公司（XAIR）2024年第四季度業績會簡介：
Financial Performance:
金融業績：
FY 2024 revenue reported at $1.2 million, up from zero in the previous year.
Net loss improved slightly to $64.3 million; cash reserves stood at $34.5 million.
2024年營業收入報告爲120萬美元，比上一年增長了零。
淨虧損略有改善，爲6430萬美元；現金儲備爲3450萬美元。
Business Progress:
業務進展：
LungFit PH launched and used in over 50 US hospitals, treating 1,100 patients.
All hospitals renewed LungFit PH contracts with an increase in multi-year agreements.
LungFit PH在超過50家美國醫院中啓用，治療了1100名患者。
所有醫院都續簽了LungFit PH合同，並增加了多年協議。
Opportunity:
機會：
Potential market expansion with pending FDA approval for LungFit PH in cardiac surgeries.
Strategic partnerships in Asia-Pacific and plans for European market entry.
有望擴大市場，並在心臟手術方面獲得FDA批准，本年度日曆年底前實現。
在亞太地區建立戰略合作伙伴關係，並計劃進入歐洲市場。
Risk:
風險：
Delayed milestones could lower FY 2025 revenue expectations.
High dependency on LungFit PH market acceptance and updated system deployments.
延遲的里程碑可能會降低2025財年營收預期。
高度依賴LungFit PH市場接受度和更新系統的部署。
Financial Performance:
金融業績：
Beyond Air reported FY 2024 revenue of $1.2 million, a significant increase from zero revenue in the previous fiscal year.
Gross margin reported a loss of $1.3 million due to costs related to device upgrades and depreciation of prebuilt devices.
Net loss for the fiscal year 2024 was $64.3 million, slightly improved from the previous year.
Cash, cash equivalents, and marketable securities totaled $34.5 million as of March 31, 2024.
Beyond Air報告，2024財年營收爲120萬美元，較上一財年無收入顯着增長。
由於設備升級成本和預建設設備折舊費用，毛利率報告虧損130萬美元。
2024財年淨虧損爲6430萬美元，與上年略有改善。
截至2024年3月31日，現金、現金等價物和可交易證券總計3450萬美元。
Business Progress:
業務進展：
Beyond Air successfully launched LungFit PH following FDA approval and completed a crucial software upgrade.
Over 50 hospitals in the U.S. have used LungFit PH to treat more than 1,100 patients totaling over 75,000 therapy hours.
All hospitals using LungFit PH renewed their contracts, with a significant increase in multi-year contracts.
Anticipation of FDA approval for the expansion of LungFit PH label to include cardiac surgery by the end of calendar year 2024.
Beyond Air成功推出LungFit PH，並完成了至關重要的軟件升級。
美國超過50家醫院使用LungFit PH治療了1100名患者，治療時間超過75000小時。
所有使用LungFit PH的醫院都續簽了合同，並增加了多年協議。
期待FDA在2024年日曆年底前批准LungFit PH標籤擴展，包括心臟手術。
Opportunities:
機會：
Significant market opportunity with the expansion of LungFit PH label to include cardiac surgeries pending FDA approval.
Establishment of strategic partnerships for the commercialization of LungFit PH in Asia-Pacific regions through Getz Healthcare.
Plans to target European markets pending CE Mark approval.
Introduction of David Webster as Chief Commercial Officer to spearhead market expansion and commercial strategies.
LungFit PH標籤擴展至包括心臟手術待FDA批准，市場機會巨大。
通過蓋茨醫療在亞太地區建立戰略合作伙伴關係，以推廣LungFit PH商業化。
計劃在CE認證獲批後進軍歐洲市場。
介紹David Webster作爲首席商業官，主導市場擴張和商業策略。
Risks:
風險：
Delays in reaching business and product milestones have adjusted revenue expectations downward for fiscal year 2025.
High dependency on successful market expansion and acceptance of updated LungFit PH systems in new hospitals.
Depreciation costs and suboptimal warehousing impacting gross margins.
未能達到業務和產品里程碑的延誤，已將營業收入預期下調至2025財年。
對成功市場拓展和新醫院更新LungFit PH系統的接受度高度依賴。
折舊成本和次優的倉儲對毛利率產生影響。
More details: Beyond Air IR
更多詳情：Beyond Air IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。